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Abstract
Leukocyte-endothelial cell interactions are mediated by various cell adhesion molecules. These interactions
are important for leukocyte extravasation and trafficking in all domestic animal species. An initial slowing of
leukocytes on the vascular endothelium is mediated by selectins. This event is followed by (1) activation of β2
integrins after leukocyte exposure to cytokines and proinflammatory mediators, (2) adherence of leukocyte
β2 integrins to vascular endothelial ligands (eg, intercellular adhesion molecule-1 [ICAM-1]), (3)
extravasation of leukocytes into tissues through tight junctions of endothelial cells mediated by platelet and
endothelial cell adhesion molecule-1 (PECAM-1), and (4) perivascular migration through the extracellular
matrix via β1 integrins. Inhibiting excessive leukocyte egress and subsequent free radical-mediated damage
caused by leukocyte components may attenuate or eliminate tissue damage. Several methods have been used
to modify leukocyte infiltration in various animal models. These methods include nonspecific inhibition of
pro-inflammatory mediators and adhesion molecules by nonsteroidal anti-inflammatory drugs (NSAIDs) and
glucocorticoids, inhibition of cytokines and cytokine receptors, and inhibition of specific types of cell
adhesion molecules, with inhibitors such as peptides and antibodies to β2integrins, and inhibitors of selectins,
ICAMs, and vascular cell adhesion molecule-1 (VCAM-1). By understanding the cellular and molecular
events in leukocyte-endothelial cell interactions, therapeutic strategies are being developed in several animal
models and diseases in domestic animal species. Such therapies may have clinical benefit in the future to
overcome tissue damage induced by excessive leukocyte infiltration.
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Cell Adhesion Molecules, Leukocyte Trafficking, and Strategies to
Reduce Leukocyte Infiltration
Zaher A. Radi, Marcus E. Kehrli, Jr., and Mark R. Ackermann
Leukocyte-endothelial cell interactions are mediated by various cell adhesion molecules. These interactions are important for
leukocyte extravasation and trafficking in all domestic animal species. An initial slowing of leukocytes on the vascular endothelium
is mediated by selectins. This event is followed by (1) activation of 2 integrins after leukocyte exposure to cytokines and pro-
inflammatory mediators, (2) adherence of leukocyte 2 integrins to vascular endothelial ligands (eg, intercellular adhesion molecule-
1 [ICAM-1]), (3) extravasation of leukocytes into tissues through tight junctions of endothelial cells mediated by platelet and
endothelial cell adhesion molecule-1 (PECAM-1), and (4) perivascular migration through the extracellular matrix via 1 integrins.
Inhibiting excessive leukocyte egress and subsequent free radical-mediated damage caused by leukocyte components may attenuate
or eliminate tissue damage. Several methods have been used to modify leukocyte infiltration in various animal models. These
methods include nonspecific inhibition of pro-inflammatory mediators and adhesion molecules by nonsteroidal anti-inflammatory
drugs (NSAIDs) and glucocorticoids, inhibition of cytokines and cytokine receptors, and inhibition of specific types of cell adhesion
molecules, with inhibitors such as peptides and antibodies to 2 integrins, and inhibitors of selectins, ICAMs, and vascular cell
adhesion molecule-1 (VCAM-1). By understanding the cellular and molecular events in leukocyte-endothelial cell interactions,
therapeutic strategies are being developed in several animal models and diseases in domestic animal species. Such therapies may
have clinical benefit in the future to overcome tissue damage induced by excessive leukocyte infiltration.
Key words: Inflammation; Integrins; Intercellular adhesion molecule-1 (ICAM-1); Neutrophils; Selectins.
Leukocyte infiltration is vital to both innate and activeimmunity. This process is an important host defense
mechanism against infectious agents, foreign antigens, and
neoplastic cells. It also occurs as a physiologic response in
cell injury due to ischemia and reperfusion, toxins, and
metabolic disturbances. When leukocyte infiltration is in
excess, however, the release of products (proteases and free
radicals [eg, O , NO]) can result in extensive tissue damage2
and subsequent fibrosis. Reducing leukocyte infiltration
may have special importance for clinical therapies and has
been the focus of studies of several diseases of humans such
as asthma, arthritis, reperfusion injuries after cerebral hem-
orrhage, and myocardial infarctions. In veterinary medi-
cine, many additional diseases are associated with extensive
leukocyte infiltration (eg, laminitis, gastric dilatation/vol-
vulus in dogs, mastitis, reperfusion injury after tissue is-
chemia in recumbent cattle and horses, and Mannheimia
[Pasteurella] haemolytica pneumonia), and strategies to re-
duce leukocyte infiltration have been developed as a ther-
apeutic approach.
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The purpose of this article was to review the structure,
expression, and function of the various cell adhesion mol-
ecules, with special attention to studies in domestic animal
species. The molecular events in leukocyte-endothelial cell
interactions and current therapeutic approaches that target
adhesion molecules also are reviewed.
Adhesion Molecules Regulating Leukocyte
Trafficking
Leukocyte adherence to the vascular endothelium is me-
diated by a sequence of binding between adhesion mole-
cules expressed on leukocytes and adhesion molecules ex-
pressed by the intraluminal and intercellular membranes of
vascular endothelial cells. Neutrophils, for example, express
selectins that adhere transiently to selectin receptors on the
endothelial cell surface (Fig 1). During vasodilation, intra-
vascular hydrostatic pressure reduces neutrophil flow
through the vessel and allows additional selectin-selectin
receptor binding events that eventually slow neutrophil cir-
culation in a tethering-like fashion. Upon activation, neu-
trophils shed some selectin molecules and greatly enhance
expression of 2 integrins that bind intercellular adhesion
molecules (ICAMs) expressed on activated endothelial
cells. Neutrophils migrate through the intercellular junc-
tions of endothelial cells, and this process is partly mediated
by other adhesion molecules (eg, PECAM-1), and extra-
vascular migration of neutrophils utilizes additional adhe-
sion molecules (eg, 1 integrins).
The importance of these molecules is underscored by the
severity of disease that can occur when even one family of
adhesion molecules is lacking or nonfunctional. In Irish
Setter dogs and Holstein cattle, functional expression of the
2 integrins by leukocytes and transmigration by neutro-
phils through the vascular endothelium into sites of infec-
tion can be markedly impaired.1,2 Affected animals often
develop severe infections of mucosal surfaces and die
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Fig 1. Phases of leukocyte infiltration from the vascular space into sites of infection and various adhesion molecules involved and modulation
of these adhesion molecules are outlined in each phase. In the 1st phase, tethering occurs via L- and P-selectin, followed by selectin-mediated
rolling in which cells gradually slow down. These phases can be inhibited by dexamethasone (DXM), antisense oligonucleotides (ASOs), mono-
clonal antibodies (mAbs), selectin mimetic (TBC), and sialyl Lewis x analog (sLex). Tight adhesion between the expressed 2 integrin can be
inhibited by DXM, mAbs, synthetic peptide analogs (SPs), and NPC 15199 (N-[fluorenyl-9-methoxycarbonyl-L-leucine]). Intercellular adhesion
molecule-1 (ICAM-1) can be inhibited by mAbs and ASOs and occurs after activation by cytokines (eg, interleukin-1 [IL-1] and tumor necrosis
factor [TNF]) and pro-inflammatory mediators (eg, lipopolysaccharide [LPS]). The actions of these cytokines and pro-inflammatory mediators
can be inhibited by mAbs, cytokine, nonsteroidal anti-inflammatory drugs (NSAIDs), receptor antagonists (RAnt.), and CD14 receptor antagonists
(CD14R Ant.). Finally, egress of leukocytes occurs via platelet and endothelial cell adhesion molecule-1 (PECAM-1) and binding to extracellular
matrix proteins via 1 integrins and other integrins.
shortly after birth. Cattle affected by bovine leukocyte ad-
hesion deficiency (BLAD) often die of alimentary tract in-
fections or pneumonia. Similar defects in 2 integrin ex-
pression occur in humans (leukocyte adhesion deficiency-
1, [LAD-1]); however, the clinical course of LAD-1 in hu-
mans varies depending on the location of the mutation in
the 2 integrin molecule. Clinical manifestations in LAD-1
and other adhesion deficiencies of humans often include
recurrent mucosal infections, as in affected cattle and dogs.
Other rare adhesion molecule deficiencies in humans in-
clude impaired 2 integrin conformational change (LAD-1
variant), impaired expression of selectin receptor expres-
sion (leukocyte adhesion deficiency-2, [LAD-2]), and ex-
cessive proteolytic cleavage of 1 type of selectin (E-selec-
tin).3–7
Selectins
Initial leukocyte rolling on vascular endothelium is me-
diated by selectins. Selectins (L-, E-, and P-selectins) are
heavily glycosylated membrane proteins.7 Structurally, se-
lectins contain an N-terminal lectin domain, an epidermal
growth factor (EGF)-type domain, several complement reg-
ulatory repeats, and a short cytoplasmic domain. The ter-
minal lectin domains of selectins bind fucosylated tetrasac-
charides of selectin receptors (sialyl Lewisx [sLex]) in the
presence of calcium (Ca2). Two types of selectin deficien-
cies are reported in humans: LAD type II (impaired fuco-
sylated tetrasaccharide production) and enhanced cleavage
of E-selectin. Although transgenic mice deficient in selec-
tins or selectin ligands have impaired leukocyte adherence,
no reports of naturally occurring selectin deficiencies in an-
imals have been reported.
L-selectin (CD62L, or leukocyte endothelial cell adhe-
sion molecule-1 [LECAM-1]) is a glycoprotein that is con-
stitutively expressed and functional on all leukocytes.8,9 L-
selectin is located on the tips of microvillus-like projections
of the leukocyte surface and interacts reversibly with its
endothelial cell ligand. L-selectin vascular endothelial cell
ligands include glycoprotein cell adhesion molecule-1
(GlyCAM-1), mucosal addressin cell adhesion molecule-1
(MAdCAM-1), cell surface carbohydrate structures that
possess a specific sLex structure, and CD34.10,11 L-selectin
undergoes a conformational change during cellular activa-
tion by pro-inflammatory substances such as C5a and leu-
kotriene B4. Activation of L-selectin increases binding af-
finity to its ligand.12,13 After L-selectin mediates slow roll-
ing of leukocytes on the vascular endothelium, proteases
induce shedding of L-selectin from the leukocyte surface.
Leukocytes of humans and animals (eg, baboon, cattle,
dog, cat, rabbit, mouse, sheep, and pig) express L-selec-
tin,8,14–24 and L-selectin is structurally conserved among bo-
vine, human, and murine species.9,25 Expression of L-selec-
tin by bovine  T cells is much higher than that of bovine
 T and B cells.26–29 The significance of this high concen-
tration of expression remains to be determined, but calves
have a relatively high number of  T cells, and selectin
adherence may be very critical to the activity of these cells
and immune surveillance.
A soluble form of L-selectin has been found in human
plasma and may have a role in preventing leukocyte-vas-
cular endothelium interaction, thus regulating the extent of
leukocyte infiltration.30,31 Selectin-mediated leukocyte roll-
ing on vascular endothelium also can be inhibited by anti-
bodies to leukocyte L-selectin32 and synthetic mimetics.
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P-selectin (CD62P, originally identified as a platelet gran-
ule membrane protein-40 or GMP-40) is stored preformed
in the  granules of platelets and Weibel-Palade bodies of
endothelial cells.33,34 P-selectin is mobilized from storage
granules to the cell surface after activation (eg, by lipo-
polysaccharide [LPS], tumor necrosis factor alpha [TNF-
], interleukin-1 [IL-1], oxygen radicals, histamine, throm-
bin, and interferon gamma [IFN-]) that causes phosphor-
ylation of tyrosine, threonine, and serine residues in its cy-
toplasmic tail.35 This process occurs by fusion of secretory
granules with the plasma membrane.36 Increased P-selectin
expression serves to slow leukocyte rolling. P-selectin
binds to the aminoterminal region of its ligands, P-selectin
glycoprotein ligand-1 (PSGL-1), and sLex on endothelial
cells and platelets and GlyCAM-1 on endothelial cells. The
interaction of the P-selectin cytoplasmic domain with clath-
rin-coated pits enhances leukocyte adhesion.37 After its
transient appearance on the cell surface, P-selectin is inter-
nalized for lysosomal degradation and may be recycled to
facilitate egress of other leukocytes entering the area.34,38
P-selectin has been studied in humans and many animals
(dog, cat, cattle, and sheep).39–44 In the dog, P-selectin ex-
pression on endothelial cells is increased in various skin
diseases,45 and in both lambs and cats, inhibition of P-se-
lectins protects the myocardium from postischemic reper-
fusion injury.41,44 A soluble form of P-selectin has been
found in the circulation of healthy humans.46 The blood
concentrations of soluble P-selectin are high in many dis-
ease conditions (eg, thrombotic thrombocytopenic purpura,
hemolytic-uremic syndrome, chronic obstructive pulmo-
nary disease, myocardial infarction, hypercholesterolemia,
and rheumatoid arthritis).46–50 As with soluble L-selectin,
the activity of the soluble form of P-selectin may be down-
regulated, and its concentration may be useful in monitor-
ing disease severity. Increases in soluble adhesion mole-
cules may be associated with extensive and possibly ex-
cessive leukocyte infiltration or recurrence of an otherwise
stable condition.
E-selectin (CD62E), previously known as endothelial
leukocyte adhesion molecule-1 (ELAM-1), is synthesized
and expressed by endothelial cells. E-selectin expression is
induced by cytokines (eg, IL-1 and TNF-) and other pro-
inflammatory molecules (eg, LPS) in acute and chronic in-
flammatory responses.51 E-selectin expression peaks about
4–6 hours after initiation of inflammation and declines to
basal concentrations after 24–48 hours. Sialylated and fu-
cosylated molecules such as sLex and sLea oligosaccharides
and E-selectin ligand-1 (ESL-1) on leukocytes are the li-
gands for E-selectin.52 Increased binding of E-selectin to its
ligand on leukocytes is regulated both by the number of
molecules expressed on the endothelial cells and by con-
formational changes that occur with cellular activation. Nu-
clear factor-K B (NF-K B) is involved in E-selectin activa-
tion.53 After expression, E-selectin is internalized by en-
docytosis and delivered to lysosomes for degradation (Table
1).54
Integrins
Integrins are required for firm leukocyte-endothelial cell
adherence. They also act as cell surface receptors that me-
diate cell-cell interactions and attachment to the extracel-
lular matrix, and they require divalent cations (eg, Ca2 and
Mg2) for adherence to their ligands. Integrins are glyco-
protein heterodimers composed of noncovalently linked 
and  transmembrane subunits. Eight  subunits and 16 
subunits have been identified.55 Different combinations of
the  and  units result in a wide variety of adherence
specificity by the heterodimers. The different subfamilies
that can be defined by their  subunit on leukocytes include
1 through 8 integrins (Table 1).
The 1 integrins share a common  subunit (CD29) and
were originally termed very late activation (VLA) integrins.
These VLA integrins are composed of at least 6 members
(VLA-1, -2, -3, -4, -5, and -6). The 1 integrins are ex-
pressed by leukocytes and are important for leukocyte in-
filtration into perivascular stroma.56 1 integrins generally
mediate cell-extracellular matrix interactions (eg, with col-
lagen, fibronectin, laminin, and vitronectin). Specialized re-
gions of fibronectin peptides (eg, arginine-glycine-aspartate
[RGD]) and other extracellular matrix proteins are ligands
for 1 integrins. Several cytoplasmic domains of the 1 in-
tegrin subunit interact with cytoskeletal actin filaments via
-actinin.57 Such interactions of integrins with the leuko-
cyte cytoskeleton are important for chemotaxis of leuko-
cytes across the perivascular adventitia and extracellular
matrix.
VLA-4 (the 41 integrin) is expressed by both B and T
lymphocytes, basophils, eosinophils, monocytes, and mac-
rophages and, to a minor degree, by neutrophils. VLA-4 is
an important ligand for VCAM-1 as well as extracellular
matrix components such as fibronectin, vitronectin, and col-
lagen. VLA-4 binds to specific domains on fibronectin such
as the connecting segment-1 (CS-1)58 and the fibronectin
RGD domain.59 VLA-4/VCAM-1 adherence is especially
active in monocyte transendothelial migration and plays a
role in cattle with BLAD and in humans with LAD type 1.
In both BLAD and LAD type 1, the numbers of neutrophils
in blood are greatly increased because of their inability to
adhere to the vascular endothelium. Although neutrophils
lack or have minimal expression of VLA-4, other leuko-
cytes express VLA-4 and presumably utilize VLA-4/
VCAM-1 binding as well as selectins to pass across the
vascular endothelium.
The 51 integrin is a major fibronectin receptor that is
regulated by divalent cations (eg, Mg2 and Ca2).60 The
51 integrin plays a role in repair of airway epithelium
after injury.61 Also, it has been found that the IpaB, IpaC,
and IpaD proteins of Shigella flexneri can interact with the
51 integrin and may facilitate leukocyte trafficking in the
alimentary tract.62
The 2 integrin subfamily consists of 4 distinct  chains
(CD11a, CD11b, CD11c, and CD11d) and a common 
chain (CD18). The structure of CD18 is highly conserved
among human, avian, murine, and bovine species.63,64 Nu-
merous cytokines such as TNF-, IL-1, interleukin-8 (IL-
8), and other pro-inflammatory molecules, such as platelet-
activating factor (PAF), leukotrienes, and LPS, increase 2
integrin expression. Leukocyte function antigen-1 (LFA-1;
L2; CD11a/CD18) is expressed by all leukocytes and in-
teracts with ICAM-1 and ICAM-2 on vascular endothelial
cells. ICAM-4 and ICAM-5 also bind to LFA-1. Mac-1
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Table 1. Summary of adhesion molecules.a
Common name CD Expressed on Binds Expressed on
Integrins
1 integrins:
VLA-1
VLA-2
VLA-3
VLA-4
VLA-5
VLA-6
2 integrins:
LFA-1
Mac-1
gp150,95
d2
3 integrins:
(CD29):
(CD49a)
(CD49b)
(CD49c)
(CD49d)
(CD49e)
(CD49f)
(CD18):
(CD11a)
(CD11b)
(CD11c)
(CD11d)
(CD61):
ec
ec
ec
L
ec
ec
L
L
L
MQ, CD8 T cells
Collagen
Collagen
Fibronectin
VCAM-1
Fibronectin
Laminin
ICAM-1
ICAM-1
ICAM-1
ICAM-3
ECM
ECM
ECM
ec
ECM
ECM
ec
ec, L
ec
L, ec
IIb3
v3
4 integrins:
64
5 integrins:
v5
6 integrins:
v6
7 integrins:
4
e
8 integrins:
v8
Platelets
ec, MQ, M
ec, SC
ec, epithelia
epithelia
ec, Lympho
Intraepith
Lympho
Fibrinogen
Fibronectin
Laminin
Vitronectin
Fibronectin
MAdCAM-1, VCAM-1
E-cadherin
Laminin
ec
ECM
ECM
ECM
ECM
ec
ec
ECM
Immunoglobulin superfamily
ICAM-1
ICAM-2
ICAM-3
ICAM-4
ICAM-5
VCAM-1
PECAM-1
MAdCAM-1
(CD54)
(CD102)
(CD50)
(CD106)
(CD31)
ec, epithelia, SC
PMN, MQ
ec, Lympho
ec, Lympho, PMN, M
Red blood cells
Subset of neurons
ec
ec, L
ec (mucosal)
2-integrins
2-integrins
2-integrins
2-integrins
2-integrins
VLA-4
PECAM-1
L-selectin
47-integrin
L
L
L
L
L
L (except PMN)
ec, L
PMN, Lympho
Selectins
L-selectin
E-selectin
P-selectin
(CD62L)
(CD62E)
(CD62P)
L
ec
ec, platelets
GlyCAM-1, CD34, MAdCAM-1
ESL-1, sLex
PSGL-1, GlyCAM-1, sLex
ec
L
ec, P
CD, cluster determinant; ec, endothelial cells; ESL-1, E-selectin ligand; ECM, extracellular matrix; GlyCAM-1, glycoprotein cell adhesion
molecule-1; L, leukocytes; M, monocytes; MAdCAM-1, mucosal addressin cell adhesion molecule-1; MQ, macrophages; PMN, polymorphonu-
clear cells (neutrophils); PSGL-1, P-selectin glycoprotein ligand; Lympho, lymphocytes; SC, Schwann cells; sLex, sialyl lewis x; see text for
definition of adhesion molecule abbreviations.
a This table is not comprehensive.
(M2; CD11b/CD18) and gp150,95 (X2; CD11c/CD18)
are expressed by macrophages and granulocytes and also
bind ICAM-1 but not ICAM-3.65 CD11d/CD18 was 1st de-
scribed in the dog and is expressed constitutively by mac-
rophages, including synovial macrophages and splenic red
pulp macrophages. CD11d/CD18 expression by leukocytes
is restricted to CD8 lymphocytes in the splenic red pulp
in dogs.66,67 The canine CD11d/CD18 (d2) heterodimer
on leukocytes has homology to human d2.66 In contrast
with other 2 integrins, the d2 integrin binds only to
ICAM-3.66,68 Although the d2 integrin has not been de-
scribed in cattle, bovine ICAM-3 has been sequenced from
a mammary gland cDNA library (Table 1).69
Deficiency in 2 integrin expression in Holstein calves is
due to a single-point mutation (adenine→guanine) at posi-
tion 128, resulting in a single amino acid change (aspartic
acid→glycine) in the  subunit (CD18) of the 2 inte-
grin.2,70,71 This defect occurs in a highly conserved extra-
cellular region (aa 96-389). A 2nd, silent mutation also has
been detected in cattle with BLAD and does not alter the
amino acid sequence. In Irish Setters with canine LAD
(CLAD), a single missense mutation results in a G to C
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conversion at nucleotide 107 of the cDNA sequence, re-
sulting in a serine residue that replaces a highly conserved
cysteine residue.1 Although cattle with BLAD, dogs with
CLAD, and humans with LAD-type 1 have high numbers
of neutrophils in the blood, these neutrophils are character-
ized by impaired passage across vascular endothelium and
numerous other functional abnormalities related to inade-
quate membrane adherence. Affected cattle develop severe
gingivitis, tooth loss, oral ulcers, enteric ulcers, cutaneous
ulcers and abscesses that lack exudate formation, and pneu-
monia.2,70 The hallmark lesion histologically is a sparse in-
filtration of neutrophils into an ulcerated mucosal surface
despite high numbers of neutrophils within the vascular lu-
mens of submucosal blood vessels. No effective treatments
are available for calves and Irish Setters, but one of the
authors (MEK) has observed 2 cattle with BLAD that sur-
vived into adulthood with intensive medical care. In hu-
mans, LAD type I varies in severity, depending on the lo-
cation of the CD18 mutation. People with severe phenotype
(expressing 1% of functional 2 integrin) often are sus-
ceptible to severe infections, whereas those with moderate
phenotype (3–10% expression) can live to adulthood.3
In the lung, 2 integrins mediate neutrophil infiltration
into various microanatomic regions. Initial neutrophil infil-
tration into bronchi and bronchioles requires functional 2
integrins in cattle.72 However, CD18-deficient neutrophils
in calves with BLAD can readily infiltrate pulmonary al-
veoli after intrabronchial deposition of M haemolytica,73
which suggests that additional adhesion molecules mediate
neutrophil infiltration into alveoli. Recent work in a rat
model suggests that sequestration of neutrophils in pulmo-
nary alveolar capillaries involves adherence of several dif-
ferent adhesion molecules, including 2 1 integrins (41
[VLA-4] and 51 [VLA-5]), 2 integrins, and selectins.74
Stiffening of neutrophils by actin polymerization is a phys-
ical change that further enhances neutrophil sequestration
in alveolar capillaries.74 The type of inoculum is an impor-
tant factor for neutrophil migration into the lung. Esche-
richia coli induces a CD18-dependent type of neutrophil
migration, whereas Staphylococcus aureus induces a CD18-
independent type of migration.75,76 In addition, the duration
of pneumonia also affects 2 integrin-mediated infiltration
into the lung. In a rabbit model, a CD18-dependent mech-
anism was observed in acute pulmonary inflammation, and
a CD18-independent mechanism was identified in chronic
inflammation.77 The ability of 2 integrins to mediate neu-
trophil infiltration into precise regions of the lung may
make it possible to site direct neutrophil infiltration into a
location of interest (eg, bronchi and bronchioles). Such a
therapeutic approach, if refined, may allow better treatment
of tracheitis and bronchitis.
The 3 integrins (CD61) include IIb3 and v3. The 3
integrins generally mediate adherence to extracellular ma-
trix ligands and clotting factors. 3 integrins recognize fi-
bronectin, fibrinogen, vitronectin, and von Willebrand fac-
tor (vWF).
The IIb3 integrin is expressed by platelets and has a
major role in platelet aggregation, which results from fi-
brinogen or vWF binding to IIb-3 complexes.78 Mutations
in the  or  subunits of the IIb3 integrin may lead to
increased susceptibility to bleeding as described in Glanz-
mann thrombasthenia, a heterozygous disease in humans.79
Homozygous defects result either in diminished function or
impaired expression of the protein on platelets. In dogs,
Glanzmann thrombasthenia has been reported in the Great
Pyrenees and Basset Hound breeds.80,81 These molecules are
important targets for antithrombolytic treatments of myo-
cardial infarction, stroke, phlebitis, and reperfusion injury.
The v3 integrin is expressed on endothelial cells,
monocytes, macrophages, and vascular smooth muscle
cells. It mediates endothelial cell adhesion and proliferation
and also has a role in angiogenesis.82 In a rabbit model of
angioplasty, iliac artery intimal hyperplasia was reduced by
v3 integrin inhibitors.83 Inhibition of integrins that me-
diate angiogenesis in neoplasms is an important area of
cancer research,84,85 whereas enhancement of angiogenic in-
tegrins may be beneficial for wound healing, as in diabetic
patients with ulcers, for example.
The 64 integrin is a laminin and kalinin receptor ex-
pressed by various cell types (eg, epithelial cells, endothe-
lial cells, and Schwann cells).86–88 The 64 integrin may
play a role in epithelial integrity by forming a link between
the plasma membrane and the basement membrane.89,90
Loss of cellular adherence to laminin and adjacent cells
leads to enhanced cellular invasion by neoplastic cells. The
64 integrin may be important in tumor progression by
facilitating a phosphatidylinositol 3-kinase (PI3K)-depen-
dent invasion via cooperative interaction between the 64
integrin and erb B-2.91
The 47 integrin is expressed in high concentration by
a subset of lymphocytes that are home to gut-associated
lymphoid tissue (GALT).92,93 It is constitutively expressed
by peripheral blood B lymphocytes but is absent on resident
B cells in tissues and is weakly expressed by resting pe-
ripheral blood T lymphocytes. The 47 integrin also is
expressed by human endothelial cells in vitro and in vivo.94
It also binds and mediates cell attachment to MAdCAM-1,
VCAM-1, and fibronectin.95 MAdCAM-1 binding is im-
portant in lymphocyte trafficking to Peyer’s patches and
intestinal mucosa. The 47 integrin also mediates lympho-
cyte binding to E-cadherin for adherence of endothelial
cells.96 Modulation of lymphocyte homing may be benefi-
cial in reducing the severity of autoimmune diseases such
as lupus erythematosus or diseases characterized by exces-
sive cell-mediated immunity (eg, inflammatory bowel dis-
ease).
Immunoglobulin Superfamily of Adhesion
Molecules
The immunoglobulin superfamily adhesion molecules are
involved in leukocyte-endothelial cell interactions. These
proteins include ICAMs, VCAM-1, and PECAM-1. ICAMs
are members of the immunoglobulin superfamily of pro-
teins and include ICAM-1, ICAM-2, ICAM-3, ICAM-4,
and ICAM-5. ICAMs are expressed by endothelial cells and
bind to 2 integrins, LFA-1, and Mac-1.97,98
ICAM-1 (CD54) is an 80–115-kd surface glycoprotein
that is composed of 5 immunoglobulin domains, a trans-
membrane domain, and a short cytoplasmic sequence. It is
constitutively expressed at low concentration on resting en-
dothelium. ICAM-1 also is expressed by Schwann cells and
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plays a role in the pathogenesis of inflammation in the pe-
ripheral nerve.99 Neutrophils and macrophages express
ICAM-1 in acute M haemolytica pneumonia in calves.100
Many epithelial cells (eg, keratinocytes) and other leuko-
cytes (eg, antigen-presenting cells) express ICAM-1. This
expression is important in leukocyte epithelial and mucosal
infiltration. ICAM-1 expression increases after activation by
cytokines such as IL-8, IL-1, IFN-, TNF-, and other pro-
inflammatory substances such as PAF and LPS.100,101 Im-
munoglobulin (Ig) domain 3 of ICAM-1 mediates Mac-1
binding of the 2 integrin.102,103 ICAM-1 requires divalent
cations (eg, Ca2 and Mg2) for adherence to its ligand.103
Increased ICAM-1 expression occurs by 4 hours and re-
mains high at 24 hours after pro-inflammatory stimuli.
ICAM-1 expression is important in leukocyte infiltration in
sites of tissue injury (Fig 1) and, because of its widespread
expression, ICAM-1 mediates leukocyte passage across the
vascular endothelium, skin, and between mucosal epithelial
cells. Mice with deficient ICAM-1 expression have im-
paired leukocyte migration during inflammation.104
Humans, dogs, mice, chimpanzees, cattle, and other spe-
cies express ICAM-1.101–103 Cysteine residues that are im-
portant for the Ig domain fold structure are highly con-
served in ICAM-1 in all species.103 Bovine ICAM-1 con-
tains increased numbers of serine residues in the cytoplas-
mic tail in comparison to human, canine, or murine
ICAM-1.101 The functional significance of the increase in
serine residues in bovine ICAM-1 is not known. A soluble
form of ICAM-1 (sICAM-1) plays a role in neutrophil ad-
hesion.105 sICAM-1 is released by mononuclear and endo-
thelial cells in patients with arthritis and release correlates
with the quantity of rheumatoid factors, soluble IL-2 recep-
tor, and disease severity.106,107 Also, increased concentra-
tions of sICAM-1 have been observed during myocardial
infarction.108 Increased concentrations of sICAM are there-
fore useful in monitoring clinical severity of myocardial
infarction or recurrence of disease in such patients. Certain
infectious agents, such as the human rhinovirus, can bind
ICAM-1.109 Aerosols of ICAM-1 delivered to the nasal mu-
cosa can reduce adherence of rhinovirus and decrease the
severity of clinical signs of cold.109,110 In addition, Plas-
modium falciparum induces binding of infected red blood
cells to ICAM-1, which is crucial in development of cere-
bral malaria.
ICAM-2 has 2 Ig domains and is present at low concen-
trations on resting endothelium, T lymphocytes, and B lym-
phocytes. ICAM-2 expression is not up-regulated by cyto-
kines.111 LFA-1 of the 2 integrin family is the predominant
ligand for ICAM-2 expressed by resting endothelial cells.111
Thus, ICAM-2 complements ICAM-1 in the binding of 2
integrins and leukocyte adherence.
ICAM-3 is a highly glycosylated protein with 5 Ig do-
mains that is expressed strongly on resting lymphocytes,
neutrophils, and monocytes.112 Bovine ICAM-3 mRNA is
expressed predominantly by resting neutrophils and, to a
lesser extent, by activated neutrophils.101 Because of a lack
of appropriate antibodies, no actual determination of
ICAM-3 protein expression by bovine cells has been re-
ported, and a specific function for ICAM-3 has not been
identified in cattle. However, because leukocyte accumu-
lation during mastitis is marked and cDNA for bovine
ICAM-3 has been derived from a bovine mammary gland
cDNA library, ICAM-3 may play a role in the innate de-
fense of the mammary gland.
ICAM-4 and ICAM-5 are recently discovered and less
characterized adhesion molecules of the immunoglobulin
superfamily that bind the CD11a/CD18 integrin.113,114
ICAM-4 (originally named Landsteiner-Wiener [LW] gly-
coprotein) has 2 Ig domains and is expressed on red blood
cells.112 It binds CD11a/CD18 on neutrophils and lympho-
cytes.113,114 The LW antigen is a red cell membrane glyco-
protein that requires divalent cations (eg, Mg2) for its re-
activity.115
ICAM-5 (telencephalin) has 9 Ig domains and a molec-
ular weight of 130 kd.116 It is a glycoprotein that is ex-
pressed by a subset of neurons (somato-dendritic) within
the telencephalon of the mammalian brain.117–121 ICAM-5
can bind to CD11a/CD18 expressed by T lymphocytes.121,122
ICAM-5 immunoreactivity is decreased in Alzheimer’s pa-
tients.123 A soluble form of ICAM-5 is increased in patients
with acute encephalitis and has potential in monitoring se-
verity of disease.124
VCAM-1 (CD106) is another member of the immuno-
globulin gene superfamily and has 5 Ig domains.125 VCAM-
1 is expressed at high concentration after LPS administra-
tion and cytokine activation (eg, IL-1 and TNF-) on all
vascular endothelial cells.126–129 This expression 1st appears
4–6 hours after stimulation and reaches maximal concen-
tration at 12–18 hours.127 VCAM-1 interacts with VLA-4
on different leukocytes (monocytes, lymphocytes, and eo-
sinophils but only minimally, if at all, with neutrophils) and
is up-regulated by endothelial cells in subacute and chronic
stages of inflammation and in atherosclerotic lesions.127
VCAM-1 requires divalent cations (eg, Ca2 and Mg2) for
adherence to its ligand.129 The soluble form of VCAM-1
(sVCAM-1) has angiogenic and chemotactic activity for en-
dothelial cells and chemotactic activity for monocytes in
rheumatoid arthritis.130,131 sVCAM-1 also induces T cell in-
filtration during synovial inflammation by an IL-2–depen-
dent mechanism.132 sVCAM-1 is up-regulated in several
disease states (eg, myocardial infarction, type 2 diabetes
mellitus, primary antiphospholipid syndrome, and rheu-
matoid arthritis).131–135
PECAM-1 (CD31) is an important 130-kd transmem-
brane glycoprotein immunoglobulin adhesion molecule that
plays a role in leukocyte transendothelial migration.136 PE-
CAM-1 is highly expressed at the intercellular junction of
endothelial cells and is integral to passage of infiltrating
leukocytes between endothelial cells. PECAM-1 appears to
bind to PECAM-1 expressed on transmigrating leukocytes,
and this type of adhesion event is critical to leukocyte
egress through tight junctions.137 PECAM-1 has 6 Ig do-
mains138–140 and is expressed constitutively by endothelial
cells, platelets, natural killer cells, leukocytes, and certain
T cell subsets.136,137 The cytoplasmic domain has numerous
sites for phosphorylation of serine, threonine, and tyrosine
residues and mediates inhibition of T cell receptor signal-
ing.137 As with other adhesion molecules, PECAM-1 re-
quires divalent cations (eg, Ca2 and Mg2) for binding to
its ligand.141–143 Bovine PECAM-1 has been sequenced, and
its distribution and cellular expression have been deter-
mined by immunohistochemistry.144
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Therapeutic Implications of Leukocyte
Trafficking
Although leukocyte infiltration into sites of infection is
an important part of host defense, this infiltration, when
excessive, can cause tissue damage. This event is central to
the pathogenesis of various human and animal diseases.
Neutrophil infiltration during postischemia reperfusion can
cause excessive injury to the brain after infarcts or cerebral
hemorrhage and to the heart after infarcts.145,146 In veteri-
nary medicine, various diseases are characterized by exten-
sive neutrophil infiltration associated with tissue damage
(eg, reperfusion injury [gastric dilatation volvulus in dogs,
prolonged recumbency, and colic], and M haemolytica
pneumonia). Platelet aggregation in laminitis, lymphocyte
infiltration in autoimmune diseases, and macrophage infil-
tration in granulomas also are conditions that require leu-
kocyte adherence for development. Therefore, inhibiting
excessive leukocyte egress, aggregation, and their subse-
quent free radical-, enzymatic-, or cytokine-mediated dam-
age may reduce tissue damage. Several methods have been
used to modify the inflammatory response or leukocyte in-
filtration and decrease tissue damage. Inhibition of prosta-
glandin, leukotriene, and cytokine production reduces both
the activation of inflammatory cells and endothelial cells
and reduces adhesion molecule expression. Other therapies
such as antibodies, peptide fragments, synthetic mimetics,
and antisense oligonucleotides target adhesion molecules
more specifically.
Modulation of Cell Adhesion Molecules and
Leukocyte Trafficking
Glucocorticoids and Nonsteroidal Anti-Inflammatory
Drugs (NSAIDs)
Arachidonic acids (AAs) are biologically active lipids
derived from cell membrane phospholipids upon cell acti-
vation (eg, membrane phospholipase A2). AA metabolites
include cyclooxygenase products (prostaglandins and
thromboxanes) and lipooxygenase products (leukotrienes
and lipoxins), both of which activate leukocytes and en-
hance adhesion molecule expression. Most NSAIDs target
cyclooxygenase or lipooxygenase activities responsible for
prostaglandin and leukotriene formation. Most, if not all,
effects of NSAIDs on adhesion molecules likely occur in-
directly through inhibition of these pathways, which, in
turn, reduce the stimuli for adhesion molecule expression.
Zileuton is a specific 5-lipooxygenase inhibitor that mark-
edly reduces leukotriene B4 production.147 Other NSAIDs
(eg, aspirin, flunixin meglumine, and ibuprofen) inhibit
prostaglandin production, adhesion molecule expression,
and leukocyte infiltration. More specifically, aspirin (a cy-
clooxygenase-1 [COX-1] inhibitor) inhibits transcription
factor kappa B.148–151 In a sheep model of skin inflamma-
tion, it has been found that flunixin meglumine is a potent
cyclooxygenase inhibitor.152 Piroxicam (COX-1 inhibitor)
inhibits 2 integrin activation by interfering with confor-
mational changes that occur on activation.148,153
Glucocorticoids such as cortisol and dexamethasone re-
duce the production of both prostaglandins and leukotrienes
by inhibition of phospholipase A2. This activity modulates
leukocyte trafficking by reduction of chemotactic factors
and limitation of leukocyte and endothelial cell activation.
Cortisol and dexamethasone also reduce L-selectin expres-
sion by bovine neutrophils that normally cause leukocyto-
sis.154 Similar effects of glucocorticoids have been demon-
strated with human L-selectin expression by neutrophils.155
In one study, dexamethasone caused release of bovine 
T cells from peripheral blood.156
Inhibition of Cytokines to Reduce Cell Adhesion
Molecule Expression
Monoclonal Antibodies to Pro-Inflammatory Cytokines.
Monoclonal antibodies have been used to inhibit leukocyte
infiltration and suppress inflammation. Anti–TNF- mono-
clonal antibodies (anti–TNF--mAbs) markedly reduced
IL-1 and IL-6 production during E coli bacteremia157 and
resulted in an overall reduction of leukocyte infiltration.
Anti–TNF--mAbs have been used to treat the inflamma-
tory infiltrates in arthritis and have been found to be an
effective therapy because of their effectiveness in reducing
IL-1, IL-6, sCD14, and sICAM-1.158,159 Monoclonal anti-
bodies against IL-6 prevented lethal effects and leukocyte
activity of E coli in a mouse model of septic shock.160 Other
cytokine antagonists (eg, anti–IL-5-mAbs) also have been
used to prevent leukocyte infiltration into airway muco-
sa.161,162 In addition to monoclonal antibodies, low-molec-
ular-compound molecules have been used as anti-inflam-
matory compounds. For example a low-molecular-weight
fraction isolated from milk of dairy cows that have been
hyperimmunized with a multivalent bacterial vaccine has
been evaluated.163
Inhibition of Cytokine Receptors. Inhibition of the var-
ious pro-inflammatory cytokines (eg, IL-1 and TNF-) and
inflammatory mediators has been used as a therapeutic
strategy. Pro-inflammatory cytokine receptor antagonists
have been tested for their anti-inflammatory effects. IL-1
receptor (IL-1R) antagonists have been shown to reduce the
inflammatory response in animal models of contact hyper-
sensitivity, autoimmune encephalomyelitis, and arthritis.164–167
TNF- antagonists and soluble TNF- receptor administra-
tion have protective effects in endotoxic shock.168,169 In ad-
dition, inhibitory cytokines such as IL-4, soluble IL-4 re-
ceptor, soluble IL-2 receptor, IFN, and IL-10 have been
demonstrated to inhibit cytokine production.170,171
Other Methods of Cytokine Inhibition. IL-10 and IL-4
have been used to inhibit TNF- production and subsequent
lethal effects in endotoxemia and reperfusion injury.52,172–174
Other cytokine production inhibitors also have been used,
such as pentoxifylline (IL-6, IL-1, TNF-, and IL-8 in-
hibitor), 17 beta-estradiol (inhibits IL-6 production by os-
teoblasts), recombinant soluble CD14 (CD14 receptor an-
tagonist), and adenosine (inhibits TNF- production).175–182
Antisense oligonucleotides (ASOs) have been used exper-
imentally to inhibit inflammatory responses, including
phospholipase A2 activity.183
Inhibition of Integrins with Synthetic Peptides
and Antibodies
VLA-4 and CD18 (2 Integrin). Inhibition of tight ad-
hesion is another method to attenuate leukocyte infiltration.
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Many studies have used monoclonal antibodies against in-
tegrins to reduce infiltration in experimental models. In a
guinea pig asthma model, CD18 blockade decreased eosin-
ophils in bronchoalveolar lavage fluid,184 and mAbs to
CD18 reduced lesions of E coli O157:H7 enteritis in a rab-
bit model.185 Monoclonal antibodies directed against VLA-
4 reduced subendothelial infiltration of mononuclear
cells,186 and reduction in leukocyte accumulation occurred
after treatment with a VLA-4 mAb in experimental auto-
immune encephalomyelitis (used as a model for multiple
sclerosis).187 These types of therapies demonstrate precision
in reducing leukocyte infiltration by inhibition of specific
components of adhesion molecules but presently are not
practical because of the expense of generating such anti-
bodies and other potential problems (eg, hypersensitivity
reactions).
Some integrins bind the extracellular matrix, and frag-
ments of extracellular matrix proteins have been used to
inhibit leukocyte adherence. In a rabbit model, inhibition
of the VLA-4 integrin binding to the CS-1 domain of fi-
bronectin by a synthetic CS-1 peptide reduced arteriopathy
by reducing lymphocyte infiltration into blood vessel
walls.188 Synthetic fibronectin peptides synthesized from
several fibronectin domains were tested in vivo and found
to suppress arthritis by inhibition of extracellular matrix
binding to integrins.189 Synthetic peptides that block VLA-
4 binding to the CS-1 peptide or heparin-binding protein
reduced leukocyte binding to extracellular matrix proteins
and were effective in attenuating ischemia-reperfusion tis-
sue damage.190 Difficulties associated with large-scale pro-
duction of peptide fragments and hypersensitivity reactions
limit the availability of these products clinically.
Leumidins such as NPC 15199 (N-[fluorenyl-9-methox-
ycarbonyl-L-leucine]) and NPC 15669 (N-9H-[2,7-dimeth-
ylfluorenyl-9-methoxycarbonyl-L-leucine]) are anti-inflam-
matory compounds that reduce neutrophil infiltration by in-
hibiting Mac-1 expression on neutrophils in vivo and T
lymphocyte activation in vitro.191–194 NPC 15199 has been
shown to attenuate ileitis in a guinea pig model,195 and NPC
15669 markedly reduced neutrophil infiltration in an acetic
acid-induced model of colitis in rats.196
Inhibition of Selectins
Inhibition of the 1st steps in leukocyte trafficking may
reduce leukocyte tight adhesion, infiltration, and subsequent
associated tissue damage. Various therapeutic agents have
been used to block this step. Rolling can be inhibited by
antibodies to leukocyte L-selectin.33 L-selectin inhibition
with mAbs decreases ischemia-reperfusion injury.19 Mulli-
gan et al21 demonstrated that anti–L-selectin mAbs reduced
immune complex-induced pulmonary injury. Cortisol and
dexamethasone reduce the activity of phospholipase A2 and
down-regulate neutrophil L-selectin expression by bo-
vine15,154 and human neutrophils.155 Similarly, P- and E-se-
lectin inhibition with mAbs has been found to reduce leu-
kocyte infiltration.197–199 Inhibition of P-selectin with an
mAb has been found to reduce ischemia and reperfusion
injury.198 In the dog, mAbs against P-selectin inhibited neu-
trophil rolling on endothelial cells.41 Monoclonal antibodies
against E-selectin decrease myocardial-reperfusion inju-
ry.197 ISIS 4730 is an ASO that inhibits E-selectin mRNA
and protein by altering the mRNA splicing process.200
Selectin ligand (sLex) inhibition also may reduce leuko-
cyte damage. In a guinea pig model of pulmonary injury,
pretreatment with anti–sLex mAbs resulted in decreased
neutrophil infiltration and reduced pulmonary injury.201
Other investigators demonstrated selectin inhibition and at-
tenuation of tissue injury in sepsis with sLex.202,203 Ridings
et al204 demonstrated that treatment with a synthetic sLex
analog attenuated pulmonary injury after Pseudomonas
aeruginosa infection, as measured by improved arterial ox-
ygenation and various parameters of inflammation. In a
mouse model of neuronal injury, glycosylated sLex treat-
ment protected against leukocyte and platelet infiltration
and neuronal injury.205
A novel synthetic inhibitor of selectins, TBC1269, has
been developed by glycosylation and hydrolysis. TBC1269
(1,6-bis[3-(3-carboxymethylphenyl)-4-(2--D-mannopyra-
nosyloxy)phenyl]hexane) is a nonoligosaccharide selectin
antagonist that contains 2 mannose and 2 carboxylates and
has been tested in vitro.206 It inhibits sLex-dependent bind-
ing of HL-60 cells to E-, P-, and L-selectins and has en-
hanced activity when compared to monomeric com-
pounds.206 We have found that in an in vivo calf model,
TBC1269 decreases neutrophil infiltration into pulmonary
alveoli and decreases protein concentration in bronchoal-
veolar lavage fluid during acute M haemolytica pneumo-
nia.207,208 TBC1269 may provide an important method for
attenuating detrimental aspects of the acute inflammatory
process without eliminating the process entirely.207 In a
sheep model of asthma, TBC1269 also markedly reduced
eosinophil infiltration.209 In this model, other adhesion mol-
ecule inhibitors such as anti–VLA-4 and the drug Zileuton
have been effective in reducing asthma.210–212
Inhibition of ICAMs and VCAM-1
Monoclonal antibodies to ICAM-1 reduced renal leuko-
cyte infiltration and proteinuria.213 Wong et al214 demonstrat-
ed reduced severity of colitis in a rat model with mAbs
against ICAM-1. Leukocyte infiltration decreased after ad-
ministration of anti–ICAM-1 antibodies in monkeys with
renal allograft transplantation.215 Dexamethasone down-reg-
ulates circulating and endothelial concentration of ICAM-
1216,217 and ICAM-3218 and inhibits rhinovirus-induced
ICAM-1 up-regulation in the lung.219 ASOs have been used
to inhibit ICAM-1 and VCAM-1 expression.220 ASOs also
have been effective in reducing activity of ICAM-1 and
VCAM-1.220 Inhibition of ICAM-1 expression by ASOs af-
ter acute ischemia in renal reperfusion injury and renal fail-
ure has been evaluated.221–224 Also, ICAM-1 ASOs have
been used to prevent rejection in cardiac allografts.225 In a
mouse model of delayed-type hypersensitivity, ICAM-1
ASOs reduced ICAM-1 mRNA expression.226
In summary, leukocyte adhesion molecules are vital for
health and play important roles in disease prevention. Their
molecular characterization and functional activities are be-
coming better understood. This review has highlighted the
features of some leukocyte adhesion molecules of veteri-
nary importance. Taking advantage of these properties in
the development of therapeutic strategies for diseases of
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veterinary importance will require an understanding of
these molecules and an insight to disease pathogenesis. De-
ficiencies of leukocyte adhesion molecules can lead to se-
rious health problems and even death. However, excessive
tissue infiltration by leukocytes often leads to tissue dam-
age. Methods to alternate tissue leukocyte infiltration by
means of compounds that regulate expression or activity of
leukocyte adhesion molecules still are developing and have
potential benefits as adjuncts to current clinical therapies.
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